A Phase 4 interventional study of Hylenex in Healthy, sponsored by Halozyme Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2006-04-06.
Sponsored by Halozyme Therapeutics · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this research study to test the effectiveness of a study medication to increase how fast a solution called lactated Ringer's is absorbed when put under the skin subcutaneously. The medication to be studied is an enzyme called hyaluronidase, and is a human recombinant form of the enzyme. The drug company name for this medication is Hylenex. Hylenex was currently an investigational medication at the initiation of the study, but received FDA approval during the study. An investigational medication is a medication or formulation of a medication that is not approved by the United States Food and Drug Administration for use in this country but may be used in studies such as this one.
The study will be conducted in two sequential stages:
Stage 1: Preliminary assessment of mean flow rate and its inter-subject variability, and a comparison to IV infusion. Each subject will receive a SC infusion of 400 mL (from a 0.5 L bag) of Ringer's lactate solution in each upper arm, followed by one IV infusion of 400 mL of Ringer's lactate solution (from a 0.5 L bag). The SC injection sites will be randomized in a double-blinded fashion to receive either 150 units Hylenex or an equal volume of saline placebo injected into a Y-port in the tubing just above the catheter immediately prior to infusion. 24-gauge angiocatheters will be placed symmetrically in the SC space in both proximal upper extremities at the lateral aspect, midline halfway between the olecranon process and the inferoposterior aspect of the acromion, introduced at a 30-degree angle. A 24-gauge angiocatheter will also be placed in a vein in either the left or right forearm (per randomization). In each upper arm, Ringer's lactate solution will be infused SC by gravity (wide open) by placing the top of the fluid in a 0.5 liter bag at a height of 100 cm above the respective angiocatheter sites. After completion of both SC infusions, Ringer's lactate solution will be infused IV by gravity (wide open) by placing the top of the fluid in a 0.5 liter bag at a height of 100 cm above the angiocatheter sites. The flow rate observations in Stage 1 will be used to either confirm or adjust the proposed sample size for Stage 2, if such adjustment is necessary.
Stage 2: Dose-comparison assessment of rate of flow over the range of 150 to 1,500 units of Hylenex. Each subject will receive a SC infusion of 400 mL (from a 0.5 L bag) of Ringer's lactate solution in each upper arm. The SC injection sites will be randomized in a double-blinded fashion to either Hylenex or an equal volume of saline solution injected into a Y-port in the tubing just above the catheter immediately prior to infusion. 24-gauge angiocatheters will be placed symmetrically in the SC space in both proximal upper extremities at the lateral aspect, midline halfway between the olecranon process and the inferoposterior aspect of the acromion, introduced at a 30-degree angle. In each arm, Ringer's lactate solution will be infused SC by gravity (wide open) by placing the top of the fluid in a 0.5 liter bag at a height of 100 cm above the respective catheter sites. Subjects will be dosed in either two or three sequential cohorts.
Cohort 3, at 750 U, to be conducted ONLY if flow rate for Cohort 2 is at least 20% faster than for Cohort 1 without unacceptable toxicity in Cohort 1, or unacceptable toxicity observed in Cohort 2 and not Cohort
In each stage, safety and tolerability will be assessed through physical examination targeted at infusion sites and volume status assessment, vital signs, and adverse events.
Study Medications Hylenex recombinant (hyaluronidase human injection); rHuPH20 (Hylenex is a registered trademark of Baxter International, Inc. or its subsidiaries)
Duration: In both stages of the study, subjects who are successfully screened for the study will receive a single, one-day session of study drug administration followed by parenteral infusions, and then undergo follow-up evaluations at 1 day (in clinic) and 28 days (by telephone) after treatment.
Subject Population: Normal volunteers satisfying all entry criteria.
Planned Total Sample Size: Considering both stages, no more than a total of 70 subjects may be enrolled in this study.
Stage 1: Five evaluable subjects will be enrolled. It is anticipated that no more than a total of 10 subjects will need to be enrolled to provide 5 evaluable subjects. An evaluable subject is one who completes all 3 parenteral infusions. Subjects not meeting this criterion, including those withdrawn prematurely for reasons other than toxicity, will be replaced.
Stage 2: 15 evaluable subjects per cohort will be enrolled. An evaluable subject is one who has completed both SC infusions and has completed protocol-specified assessments sufficient for determination of safety and tolerability. Subjects not meeting these criteria, including those withdrawn prematurely for reasons other than toxicity, will be replaced. Enrollment of Cohort 3 is dependent on findings in Cohorts 1 and 2. Allowing for some non-evaluable subjects in up to three cohorts, each including 15 evaluable subjects, a total of up to 60 subjects may be entered in this Stage 2.
Stopping Rules: Safety monitoring of enrolled subjects will be ongoing and continuous. If signs or symptoms of unacceptable fluid overload occur, the subject will be withdrawn.
Halozyme Therapeutics is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Average infusion flow rate (mL/hr) derived from the time to infuse 400 mL of lactated ringers
Average SC infusion rate of flow (mL/hr) derived from time required to drain 400 mL from the 500 mL infusate bag, fluid and tubing AND for the arm circumference to return to baseline
Flow rate determined by weight of infusate bag, fluid and tubing at specified timepoints
For SC infusions, change in arm circumference in three locations in the vicinity of the site of infusion
For SC infusions, time from the beginning of infusion until arm circumference returns to baseline
Subject assessment of local discomfort by placing a mark on a 0 100 mm visual analogue scale (VAS) anchored by no discomfort and worst possible discomfort
Local edema assessed by the Investigator on a 0-4 scale
Leakage of fluid at angiocatheter site assessed by the Investigator on a 0-4 scale, prior to infusion, at mid-infusion, at end of infusion, and (for SC infusions), when arm circumference returns to baseline
Subject's global rank-ordered preference for infusion
Investigator's global rank-ordered preference for infusion
Photographic images of the SC infusion sites
Safety and tolerability, based on adverse events and PE including vital signs
The record gives a start of Nov 2005 and a completion of Jan 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyaluronidase (human recombinant)